Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 707 of 5804
-
Migraine sufferers: could a new shot cut your headache days?
Prevention CompletedThis study evaluates the efficacy of eptinezumab to prevent migraine in participants with chronic migraine.
Phase: PHASE3 • Sponsor: H. Lundbeck A/S • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
Radioactive beads offer new hope for inoperable liver cancer
Disease control OngoingThe objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C. SIR-Spheres consist of…
Phase: NA • Sponsor: Sirtex Medical • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy aims to halt spread of prostate cancer
Disease control OngoingThe purpose of this study is to assess the safety and effectiveness of radiation therapy with hormone therapy (ADT) and chemotherapy as an investigational study treatment for prostate cancer. This is a phase 2 study to deliver focal radiation with pulsed systemic therapy of Abira…
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug cocktail aims to shrink skin cancer before surgery
Disease control OngoingThis is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo shows promise for Hard-to-Treat ovarian cancer
Disease control Recruiting nowThe proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors ev…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New combo therapy offers hope for head and neck cancer patients who Can't take standard chemo
Disease control OngoingThe purpose of this research is to see what effects the treatment regimen chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab), has on patients who have been diagnosed with head/neck squamous cell carcinoma and are unable to take the drug 5-fluorouracil
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Glue embolization may cut repeat brain bleed surgery
Disease control CompletedThis is a prospective, multi-center, open-label, randomized controlled study in which subjects can receive standard of care (SOC) alone or SOC and TRUFILL n-BCA MMA embolization for the treatment of chronic subdural hematomas (cSDH).
Phase: NA • Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New strategy aims to boost surgery success in pancreatic cancer
Disease control OngoingThis phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is effective in treating patients with pancreatic cancer th…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill combo aims to fight spread of colorectal cancer
Disease control OngoingThis is an open label, randomized, phase Ⅲ study to treat subjects with RAS/BRAF wild-type, unresectable metastatic colorectal cancer. The patients will be randomized into two arms consist of Anlotinib (3 weeks/cycle) + CapeOx and Bevacizumab (3 week/cycle) + CapeOx at a ratio of…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Tiny particles, big hope: new combo tackles tough cancers
Disease control Recruiting nowThis research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and …
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for kids with IBD: Long-Term drug trial launches
Disease control Recruiting nowThe main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to partic…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a ketogenic diet boost brain cancer treatment?
Disease control CompletedGlioblastoma (GBM), a very aggressive brain tumour, is one of the most malignant of all cancers and is associated with a poor prognosis. The majority of GBM cells display damaged mitochondria (the "batteries" of cells), so they rely on an alternate method for producing energy cal…
Phase: NA • Sponsor: Waikato Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy offers hope for advanced lung cancer patients
Disease control Recruiting nowIn clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non…
Phase: PHASE2 • Sponsor: Zibo Municipal Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug combo shows promise for rare, aggressive prostate cancer
Disease control OngoingEligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may b…
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingIn this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail shows promise for tough pancreatic cancer
Disease control CompletedThe main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).
Phase: PHASE2 • Sponsor: Cardiff Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New heart valve fix without Open-Heart surgery shows promise
Disease control CompletedThe Renato® transcatheter valve-in-valve system, developed by Balance Medical, is undergoing a multicenter registry trial across China. The study enrolls patients whose previously implanted surgical or transcatheter bioprosthetic valves have deteriorated and who are at high risk …
Phase: NA • Sponsor: Beijing Balance Medical Technology Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:39 UTC
-
Nasal spray could ease stage fright for social anxiety sufferers
Symptom relief CompletedThis Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during an induced public speaking challenge. Subject part…
Phase: PHASE3 • Sponsor: VistaGen Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 26, 2026 16:19 UTC
-
Lung cancer drug combo trial halted midway
Disease control TerminatedThe purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (…
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for tough AML: drug cocktail targets resistant leukemia
Disease control Recruiting nowThis phase Ib/II trials studies the side effects of decitabine/cedazuridine (ASTX727) and venetoclax in combination with ivosidenib or enasidenib, and how well they work in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatmen…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC